Fiagon AG Medical Technologies is now part of Intersect ENT – Click here to learn more about our navigation offering.

About Intersect ENT

Intersect ENT (NASDAQ: XENT) is a medical technology company dedicated to advancing the treatment of ear, nose and throat (ENT) conditions through evidence-based innovation, providing physicians with solutions to overcome clinical challenges and improve the quality of life for patients.

Intersect ENT’s initial focus is on improving the treatment of chronic sinusitis, an inflammatory condition that affects one out of eight adults in the U.S. and has a greater impact on quality of life than congestive heart failure or chronic back pain.1,2 Chronic sinusitis often requires a complex combination of medical and surgical therapy and is hence one of the most costly conditions to U.S. employers3. While traditional surgical solutions relieve symptoms in many patients, disease recurrence is frequent with the majority of patients experiencing recurrent symptoms within the first year.4

Intersect ENT is a publicly traded company.



We make things happen. Decisive, supportive, trusting, accountable.


We do the right thing. Honest, ethical, thorough.


We assume noble intent. Flexibility, candor, dignity.


We are a team. Diversity of thought, cooperation, partnership, transparency.


We embrace complexity – we figure it out. Undaunted, first in class, transformative.


Thomas A. West

President and Chief Executive Officer


Tom was named Chief Executive Officer and a member of the Board of Directors in July 2019. Previously, he served as Division President, Diagnostics Solutions at Hologic, Inc. At Hologic, he delivered consistent,above-market revenue growth rates in the domestic and international diagnostics business, achieving over $1.1 billion in worldwide diagnostics sales and reversing previous declines. Prior to Hologic, Tom held various roles of increasing responsibility at Johnson & Johnson, including serving as Worldwide Vice President of Strategy and Business Development for Johnson & Johnson’s Diabetes Solutions Companies. He also served as President of LifeScan North America and as President of LifeScan EMEA. Tom earned a Bachelor’s degree in politics and economics from Princeton University and a Master of Business Administration from the Wharton School at the University of Pennsylvania.

Randy Meier

Randy Meier

Executive Vice President & Chief Financial Officer


Randy joined Intersect ENT in November 2019 as Executive Vice-President and Chief Financial Officer. Previously he served in various senior executive leadership positions at Owens & Minor, Inc. a global healthcare services company, including Chief Financial Officer, President-International and Executive Vice President. Prior to joining Owens and Minor, Randy served as Executive Vice President and Chief Financial Officer at Teleflex, Inc., a global medical device company. Randy held the position of President and Chief Operating Officer of Advanced Medical Optics, Inc., a global ophthalmic medical device company, when the company was acquired as a wholly owned subsidiary of Abbott Laboratories. He joined Advanced Medical Optics as Corporate Vice President and Chief Financial Officer in 2002. Randy was also a member of ICN Pharmaceuticals executive leadership team where he served as Executive Vice President and Chief Financial Officer, and as Treasurer. Randy earned a bachelor’s degree in economics from Princeton University.

Gwen Carscadden

Chief People Officer


Gwen joined the Intersect ENT team in June of 2016 as the company’s Chief People Officer with over 25 years of experience in human resources in both high technology and life sciences sectors. Prior to joining Intersect ENT, Gwen served as Senior Vice President of Human Resources at CardioDx, Inc., a privately held medical diagnostics company. Before that, Gwen held the role of Vice President of Human Resources for Facet Biotech, which was acquired by Abbott in 2010 and served as an Executive Director of Human Resources for PDL Biopharma. She began her career in the technology sector, working for Amdahl Corporation and Fujitsu Computer Systems. Gwen holds an M.A. in Organizational Communication from San Jose State University and a B.A. in Behavioral Sciences also from San Jose State.

Christine Kowalski of Intersect ENT

Christine Kowalski

Executive Vice President & Chief Operating Officer


Christine joined Intersect ENT in 2018 with more than thirty years of experience in the medical device industry, including nearly two decades in operations and supply chain executive leadership. Christine has held senior executive leadership roles overseeing operations and supply chains for several medical device companies, including ev3 (acquired by Covidien/Medtronic), American Medical Systems/Endo Healthcare Solutions (acquired by Boston Scientific), RTI Surgical, and Johnson & Johnson, where she served most recently as Vice President of Supply Chain Strategy. During her 18 years at Guidant/Boston Scientific, Christine served as Group Vice President of Operations for Vascular Access, Vice President of Global Operations for Vascular Intervention, General Manager of Guidant Puerto Rico’s manufacturing operation, and Vice President of financial audit and reengineering. She earned a bachelor’s degree from the University of North Dakota and a masters in management from Purdue University’s Krannert School of Management.


Intersect ENT, Inc. declares that, as part of our continued focus on compliance, we have developed a Comprehensive Compliance Program that, to the best of our knowledge and as of the date of this declaration, substantially complies with the requirements of California Health & Safety Code §§ 119400- 119402. Copies of this declaration may be obtained by calling 866-531-6004.  April 1, 2020

1National Health Interview Survey 2006. CDC National Center for Health Statistics. Series 10 Number 235.
2Gliklich et al. Otolaryngol Head Neck Surg. 1995;113:104-9.
3Rudmik L et al. Curr Allergy Asthma Rep. 2017;17:20.
4Shaitkin et al. Laryngoscope. 103 Oct 2003.